Public health groups raise concern on patent grant to promising, new HIV drug Patient and public health groups have raised concerns over a potential patent grant to Gilead Sciences for the HIV drug ...

PURPOSE ...

Three Motley Fool contributors think they've identified dirt-cheap healthcare stocks to buy right now. Here's why they picked ...

Ending Acquired Immune Deficiency Syndrome (AIDS) as a public health threat here by 2030 will take much effort as it will all around the world. The key, ...

There are now multiple forms of injectable PrEP medications. Lenacapavir, which is Gilead's injectable drug, differs from ...

Discover the latest updates on the Global Fund's efforts in combating AIDS, Tuberculosis, and Malaria amidst challenges posed ...

Gilead Sciences (GILD) stock price has staged a strong comeback this year, helped by strong earnings and a recent $40 million ...

Peter Sands, head of the Global Fund, warned that climate change and conflict could undermine health improvements. Despite progress, funding concerns persist for 2026-2028 efforts. The 2024 report ...

Twice-yearly lenacapavir was found to be superior to daily emtricitabine 200mg and tenofovir disoproxil fumarate 300mg.

The process for translating clinical trial results into action for young women in Africa has been left to our imaginations, ...

Gilead has several patent applications in India on lenacapavir. Two of these patent applications, filed in 2020, seek patents ...

It could be a real breakthrough for people at risk for HIV infection: A shot given every 6 months that reduces their risk by a whopping 96%.